Allergy Treatment

Global Allergy Treatment Market to Reach US$24.1 Billion by 2030

The global market for Allergy Treatment estimated at US$19.4 Billion in the year 2024, is expected to reach US$24.1 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Asthma, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$5.9 Billion by the end of the analysis period. Growth in the Rhinitis segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.2 Billion While China is Forecast to Grow at 6.4% CAGR

The Allergy Treatment market in the U.S. is estimated at US$5.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.0 Billion by the year 2030 trailing a CAGR of 6.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Allergy Treatment - Key Trends and Drivers

Allergy treatment has become increasingly essential in modern healthcare, addressing the rising prevalence of allergic conditions worldwide. Allergies, which are hypersensitive immune responses to substances such as pollen, food, or pet dander, affect millions of individuals, causing symptoms ranging from mild discomfort to severe anaphylaxis. The primary types of allergies include respiratory allergies (such as hay fever and asthma), food allergies, skin allergies (such as eczema), and insect sting allergies. Treatment options vary depending on the type and severity of the allergy and include medications, immunotherapy, and lifestyle modifications. Antihistamines, corticosteroids, decongestants, and leukotriene inhibitors are commonly used to manage symptoms, while immunotherapy, including subcutaneous injections and sublingual tablets, offers long-term relief by desensitizing the immune system to specific allergens. The effectiveness of these treatments has made managing allergies more attainable, improving the quality of life for many patients.

A significant trend in allergy treatment is the development of targeted biologic therapies, which offer a more personalized approach to managing severe allergic conditions. Biologics, such as monoclonal antibodies, work by specifically targeting components of the immune system involved in allergic reactions. For instance, omalizumab, a monoclonal antibody used in the treatment of severe asthma and chronic urticaria, targets immunoglobulin E (IgE), a key player in allergic responses. These advanced treatments are particularly beneficial for patients who do not respond adequately to traditional therapies. Additionally, there is a growing emphasis on non-pharmacological interventions, including allergen avoidance strategies and the use of air purifiers and hypoallergenic products, to minimize exposure to allergens. Advances in diagnostic techniques, such as component-resolved diagnostics, enable more precise identification of allergen sensitivities, allowing for tailored treatment plans. The integration of telemedicine in allergy care has also improved access to specialist consultations and ongoing management, particularly in remote or underserved areas.

The growth in the allergy treatment market is driven by several factors, including the increasing prevalence of allergic conditions, advancements in biologic therapies, and the rise in awareness about allergy management. The rising incidence of allergies, influenced by factors such as environmental pollution, lifestyle changes, and genetic predisposition, has led to greater demand for effective treatments. Technological advancements in drug development have facilitated the introduction of innovative biologic therapies that provide targeted relief for severe allergies, expanding treatment options. Growing awareness about the importance of early diagnosis and proactive management of allergies has prompted more individuals to seek medical advice and adhere to treatment regimens. Furthermore, the expansion of healthcare infrastructure and the availability of over-the-counter allergy medications have made allergy treatments more accessible. The increasing adoption of telemedicine and digital health solutions is also contributing to market growth by enhancing patient access to care and improving treatment adherence. These factors collectively drive the robust growth of the allergy treatment market, ensuring better management of allergic conditions and improved patient outcomes.

SCOPE OF STUDY:

The report analyzes the Allergy Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Asthma, Rhinitis, Skin Allergy, Food Allergy, Eye Allergy, Other Types); Treatment (Anti-Allergy Drugs, Immunotherapy); Dosage Form (Oral, Intranasal, Inhalers, Other Dosage Forms)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 12 Featured) -

• ALK-Abello A/S
• Allergan PLC
• ALLERGOPHARMA GmbH & Co. KG
• Allergy Therapeutics plc
• Genentech, Inc.
• GlaxoSmithKline Plc
• Johnson & Johnson
• Merck & Co., Inc.
• Sanofi SA
• Stallergenes Greer

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.